AstraZeneca PLC (AZN)

The company now

AstraZeneca, the Cambridge drugmaker behind cancer medicines such as Tagrisso and Imfinzi, reported first-half 2026 Total Revenue of $30.7 billion, up 6 percent at constant exchange rates 1. Double-digit growth in cancer and rare-disease medicines outweighed US generic copies of Farxiga and China's volume-based procurement, a state tender system that cuts prices 1. The company kept its 2026 goal of Total Revenue growth by a mid-to-high single-digit percentage 1.

The year also brought setbacks: Wainua, a gene-silencing medicine shared with Ionis, failed its large heart trial in July, and Etcamah missed its main goal in the SERENA-4 breast cancer trial 1112. Approvals followed: Etcamah in the US in September, Ultomiris for IgA nephropathy, a kidney disease, in the US on 22 October, and Enhertu for early breast cancer in the EU on 27 October 13910.

The open question is the results for the first nine months, due on 30 October, the first figures since AstraZeneca completed a $2 billion investment in Summit Therapeutics 17. That money ties AstraZeneca to ivonescimab, Summit's experimental antibody that blocks two cancer targets at once, which AstraZeneca plans to test alongside its own antibody drug conjugates 6.

As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.